Cibc World Market Inc. Boosts Stock Holdings in Genmab A/S Sponsored ADR $GMAB

Cibc World Market Inc. raised its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 31.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 367,282 shares of the company’s stock after buying an additional 87,350 shares during the period. Cibc World Market Inc. owned approximately 0.06% of Genmab A/S worth $11,312,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Osaic Holdings Inc. increased its holdings in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after buying an additional 1,143 shares in the last quarter. Brown Brothers Harriman & Co. increased its holdings in Genmab A/S by 143.4% in the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after buying an additional 780 shares in the last quarter. Founders Capital Management increased its holdings in Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after buying an additional 400 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. HC Wainwright dropped their target price on shares of Genmab A/S from $40.00 to $38.00 and set a “buy” rating for the company in a report on Thursday, April 30th. Wolfe Research assumed coverage on shares of Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 target price for the company. Weiss Ratings cut shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. The Goldman Sachs Group raised shares of Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. Finally, Jefferies Financial Group assumed coverage on shares of Genmab A/S in a report on Tuesday, February 17th. They issued a “buy” rating and a $41.50 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.93.

Genmab A/S Stock Up 1.7%

GMAB stock opened at $25.15 on Friday. The company’s 50 day simple moving average is $26.90 and its 200-day simple moving average is $29.43. The firm has a market capitalization of $15.68 billion, a PE ratio of 19.05, a P/E/G ratio of 1.49 and a beta of 0.85. Genmab A/S Sponsored ADR has a 12 month low of $20.23 and a 12 month high of $35.43. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.